We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
- Authors
Santoleri, Fiorenzo; Lasala, Ruggero; Ranucci, Elena; La Barba, Gaetano; Di Lorenzo, Roberto; Vetrò, antonio; Di Bartolomeo, Paolo; Costantini, alberto
- Abstract
Objective: Adherence to tyrosine kinase inhibitor treatment is a significant factor in the achievement of a good clinical response in chronic myeloid leukemia (CML). The aim of this retrospective study is to investigate 1- and 2-year medication adherence to imatinib treatment, linking adherence rates with the clinical outcome, in accordance with European LeukemiaNet Recommendations for the management of CML. We have tried to find a cutoff value for adherence in order to achieve a good clinical outcome. Methods: The method used to calculate medication adherence was the ratio between the received and the prescribed daily dose. Results: We observed the levels of mean adherence for each of the following response groups (in years 1 and 2, respectively): complete response (0.96, 0.95), MR4.5 (1.00, .), MR4 (0.93, 0.91), major molecular responses (0.96, 0.97), warning (0.91, 0.89) and failure (0.79, 0.84). Conclusion: Results show that the higher the adherence, the lower the level of BCR-ABL1. Furthermore, using cutoffs. 0.9, outcomes were significantly improved compared to those with cutoffs <0.90. This value of adherence is in line with previous publications.
- Subjects
TREATMENT of chronic myeloid leukemia; PROTEIN-tyrosine kinase inhibitors; DRUG therapy; IMATINIB; PATIENT compliance; TREATMENT effectiveness
- Publication
Acta Haematologica, 2016, Vol 136, Issue 1, p45
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000444626